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135 The use of rep-PCR (Diversilab®, bioMe´rieux) in combination
with multiplex PCR (targeting virulence genes) reveals the
transmission of Pseudomonas aeruginosa isolates among cystic
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Objectives: To rapidly detect transmission of Pseudomonas aeruginosa (P. aeru-
ginosa) among cystic ﬁbrosis (CF) patients in a hospital environment, so that the
necessary measures can be taken to avoid future transmissions.
Methods: The use of molecular typing techniques such as rep-PCR (Diversilab®,
bioMe´rieux), in combination with multiplex PCR targeting ferripyoverdine receptor
genes and S-type pyocin genes to distinguish between P. aeruginosa isolates.
Conclusion: In order to quickly detect and respond to bacterial transmissions
and outbreaks in hospitals, an appropriate detection method to identify these
transmission events and strains is indispensable. Although the use of rep-PCR to
determine the clonally relatedness of potential transmissible strains is very useful,
we have shown that a combination of the latter technique together with a speciﬁc
multiplex PCR targeting virulence factors such as ferripyoverdine receptors and
pyocins allows for the accurate detection of transmission of P. aeruginosa among
CF patients in a hospital environment. We showed that intra CF patient P. aeruginosa
transmission can occur but that there is not really one highly transmissible CF clone
spreading.
136 Development of a sensor for detection of Pseudomonas
aeruginosa lung infection in the breath of CF patients
R.K. Lauridsen1. 1Technical University of Denmark, DTU Nanotech, Lyngby,
Denmark
Background: Pseudomonas aeruginosa (PA) is one of a few bacteria emitting the
poisonous gas hydrogen cyanide (HCN) to effectively outmatch competitive ﬂora
using HCN synthase to produce HCN from glycine under microaerobic conditions.
Methods: Surface-Enhanced Raman Spectroscopy (SERS) is a method which holds
great potential in the detection of small molecules at very low concentrations
because our nanostructured SERS surface enhances the Raman signal >1,000,000
times.
Objectives: The objective of the project is to further develop the nanostructured
SERS chip originally made for explosives detection to build a point-of-care sensor
able to detect hydrogen cyanide emissions in the breath of PA infected CF patients.
Results: In a serial dilution experiment on the SERS chip a direct proportional re-
lationship between the concentration of applied cyanide and the resulting enhanced
Raman signal was demonstrated. SERS measurements on physiologically relevant
concentrations of HCN gas will be presented as well as incubation results of the
SERS chip with PA in various environments.
Conclusion: Using our SERS chip it is possible to measure HCN at physiologically
relevant concentrations demonstrating the potential of detecting PA at an earlier
stage than allowed by current technology.
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Objectives: Elevated concentrations of hydrogen cyanide (HCN) have been detected
in the headspace of Pseudomonas aeruginosa (PA) cultures and in the breath of
children with cystic ﬁbrosis (CF) and PA infection. The use of mouth-exhaled
breath HCN as a marker of PA infection in adults is more difﬁcult to assess as
some without PA infection generate HCN in their mouth.
Hypothesis: The analysis of breath exhaled via the nose, thereby avoiding volatile
compounds produced in the mouth, will demonstrate elevated concentrations of
HCN in adult CF patients chronically infected with PA.
Methods: Using selected ion ﬂow mass spectroscopy (SIFT-MS), the mouth and
the nose-exhaled breaths of 20 adult CF patients; 10 with chronic PA infection and
10 free from PA infection were analysed for HCN. Acetone and ethanol were also
measured as controls. This analytical technique allows direct sampling of single
breath exhalations, obviating the need to collect samples into bags or onto traps,
which can compromise samples.
Results: HCN was detected in the mouth-exhaled breath of patients in both groups
and in the nose-exhaled breath of patients with chronic PA infection. The median
(IQR) nose-exhaled HCN was signiﬁcant higher in those with chronic PA infection
compared to those free from PA (11 (0.8−18) ppbv vs 0 (0−3.2) ppbv, p = 0.03). The
concentrations of acetone and ethanol in nose-exhaled and mouth-exhaled breath
are in keeping with previous studies.
Conclusion: HCN in nose-exhaled breath is a biomarker of chronic airway infection
with PA in adults with CF. Its application as a non-invasive diagnostic test for early
PA infection warrants further investigation.
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Background: The deﬁnitions of “chronic” and “new/early” infection are assessed
retrospectively. In order for these deﬁnitions to be consistently applied in research
practice, standardised clinical practice is required.
Objectives: To gain information on clinical practice within ECFS-CTN sites
with regards sampling and processing of respiratory samples for identiﬁcation of
P. aeruginosa.
Methods: A survey was distributed to investigators in all ECFS-CTN sites.
Results: 43 sites/subsites completed the survey giving a representative sample of
the whole group. 72% of sites had both adult and paediatric patients registered,
with remaining centres having either adults only (14%) or paediatrics only (14%).
52% of ECFS-CTN sites collected respiratory samples for routine culture at least
every 3 months (5% monthly; 43% at every hospital visit). In adult patients this
was predominantly sputum. Sites with only paediatric patients and sites with both
adults and paediatrics use a combination of sputum and oropharyngeal swabs. For
patients unable to expectorate, sites had different strategies for escalating to more
invasive methods of obtaining samples (i.e. sputum induction and bronchoalvaolar
lavage). The two main reasons for performing invasive sampling were unexplained
clinical deterioration and suspicion of non-tuberculous mycobacteria.
There was great variability in laboratory practices reported for processing (e.g.
homogenisation of samples, medium used, methods used to conﬁrm identity of
P. aeruginosa).
Conclusion: This survey highlights the challenges to research in applying deﬁni-
tions for infection retrospectively using clinical data.
